-
Estradiol, ER Stress, and T-Cell Recovery After Shock
2026-09-09
The reference study identifies endoplasmic reticulum stress as a mechanistic link between hemorrhagic shock and impaired splenic CD4+ T-lymphocyte function. Pharmacological experiments indicate that estradiol acts mainly through ERα and GPR30, rather than ERβ, to reduce this stress response and restore immune-cell activity.
-
MK-8745: Aurora A Inhibitor Workflows
2026-09-09
MK-8745 provides a potent, selective way to connect Aurora A activity with mitotic arrest, apoptosis, and tumor-response phenotypes. This practical guide translates retinoblastoma findings into cell-based assay design while covering formulation, controls, readouts, and troubleshooting.
-
PF-562271 HCl for Reliable FAK/Pyk2 Assays
2026-09-08
Learn how PF-562271 HCl, SKU A8345, can support reproducible viability, proliferation, and cytotoxicity workflows through defined FAK/Pyk2 potency, documented solvent behavior, and practical assay controls. This scenario-based guide separates target-engagement evidence from nonspecific cell loss and provides recommendations for handling, interpretation, and vendor selection.
-
CCG-1423: RhoA Inhibitor Mechanism & Use
2026-09-08
CCG-1423 is a small-molecule RhoA inhibitor that blocks MRTF-A nuclear import by disrupting its interaction with importin α/β1. Its research applications include cancer research, proliferation studies, invasion models, and apoptosis assays, while its relevance to virus-associated barrier remodeling remains a hypothesis rather than a demonstrated treatment effect.
-
PPT: Selective ERα Agonist for Reliable Assays
2026-09-07
This scenario-driven guide explains how PPT (Propyl Pyrazole Triol), a potent, selective ERα agonist, can improve experimental reasoning in viability, proliferation, and cytotoxicity workflows. It provides practical guidance for using SKU B6735, including solvent handling, receptor-selectivity controls, data interpretation, and evidence-based product selection.
-
Tetracycline Hydrochloride: Mechanism-to-Assay Guide
2026-09-05
Tetracycline Hydrochloride is a bacteriostatic antibiotic whose ribosome-level activity requires carefully matched growth, translation, and viability assays. This guide develops a mechanism-to-assay framework and explains how ROS-driven platinum research can improve experimental controls without conflating distinct biological mechanisms.
-
T-5224 Triggers Ferroptosis in Multiple Myeloma
2026-09-05
The Heliyon study linked T-5224-mediated multiple myeloma cell death to ferroptosis and suppression of PI3K/AKT signaling, extending earlier evidence that AP-1 inhibition limits myeloma growth. Its rescue experiments with ferrostatin-1 and 740Y-P, together with in vivo testing and bortezomib combination data, provide a mechanistic framework for further preclinical investigation.
-
Patient-Derived Gastric Cancer Assembloids
2026-09-04
The reference study develops patient-matched gastric cancer assembloids that combine tumor organoids with stromal cell subpopulations from the same tumor tissue. Compared with organoid monocultures, these models altered transcriptomic programs and drug responses, offering a more physiologically relevant platform for studying tumor–stroma interactions and resistance.
-
Cabazitaxel (XRP6258): Workflow Guide
2026-09-04
Cabazitaxel (XRP6258, SKU B2157) supports studies of microtubule dynamics disruption in taxane-sensitive and taxane-resistant cancer models. It is suited to DMSO- or ethanol-based workflows, but is insoluble in water and should not be maintained as a long-term solution.
-
Fosinopril Sodium: From ACE Target to Translation
2026-09-03
Fosinopril sodium offers translational researchers more than conventional ACE inhibition: its phosphinic acid zinc-binding pharmacophore, oral prodrug conversion, and renal–hepatic disposition create a framework for linking molecular target engagement with blood pressure, renal, and cardiac outcomes.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-09-02
FITC-Concanavalin A (ConA) Conjugate is a direct fluorescent probe for accessible α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids. It is suited to immunofluorescence, tissue staining, and flow cytometry carbohydrate assays, but should not be treated as a general cell-surface marker or used without validating buffer, fixation, titration, and fluorescence controls.
-
TH287 MTH1 Inhibitor: Assay Design for DNA Damage
2026-09-02
TH287, a potent MTH1 inhibitor, offers a time-sensitive way to investigate oxidized nucleotide stress and cancer-cell radiosensitization. This article translates recent CRPC findings into practical assay design, endpoint selection, and interpretation strategies.
-
Separating Growth Arrest from Cancer Cell Death
2026-09-02
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. By separating proliferative arrest from cell killing, the study provides a more informative framework for designing and interpreting in vitro cancer biology experiments.
-
Modified Ethanol Injection for mRNA Lipoplexes
2026-09-01
Tang and colleagues adapted a modified ethanol injection method to prepare mRNA lipoplexes without relying on specialized microfluidic equipment. Screening 18 lipid compositions identified DC-1-16 or TC-1-12 combined with DOPE and PEG-Chol as effective formulations, with the DC-1-16 system supporting protein expression in mouse lungs and spleen and antigen-specific IgG1 responses after immunization.
-
Protein A/G Magnetic Co-IP/IP Kit Workflow
2026-08-31
Translate protein-interaction findings into a practical workflow for isolating native complexes from cell lysates, serum, and culture supernatants. This guide shows how magnetic capture can support RNF8–DAPK1 validation, mass spectrometry preparation, and antibody purification while addressing the controls and optimization steps that determine assay quality.